# Partners Innovation Fund

> Partners Innovation Fund is a VC fund backing Biotechnology and Health Care. See 47 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 47
- Last investment: Feb 2021
- Lead investor: 9%
- Fund size: $171M
- Last fund: Nov 2016
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/partners-healthcare/
- X (Twitter): https://www.twitter.com/partnersnews
- Website: https://www.partnersinnovationfund.com/
- Facebook: https://www.facebook.com/partnershealthcare

Partners Innovation Fund is a VC fund in Boston focused on Biotechnology and Health Care. The Innovation Fund was created in 2007 by Brigham and Women's Hospital and Massachusetts General Hospital to address a growing unmet need for funding emerging technology in the capital gap between invention and product development.The main objective of the fund is to accelerate to market technologies developed by Partners HealthCareinvestigators, thereby enhancing healthcare quality, cost and outcomes. Structured as a separate LLC entity, the $35M Fund is evergreen in design and will reinvest all gains from investments back into the Fund to create capital for additional investments.Investment decision oversight is provided by an independent external committee composed of experts from industry, venture capital and academia.The Fund operates on a venture capital model whereby opportunities are rigorously evaluated on the basis of scientific strength as well as potential for commercial success.The Fund has four major goals:* Capture more value from the PHS research portfolio by creating companies, technologies and solutions that advance and enhance healthcare.* Provide funding for technologies positioned in the capital gap between invention and clinical development.* By demonstrating institutional commitment, attract external capital that will leverage and encourage co-investment.* Generate a return on investment to refresh the fund and provide capital for additional technologies.Gap FundingOver the last five to seven years, the environment for early-stage investing has undergone significant change. As a result of these changes, there is a dearth of funding support for technologies/companies positioned between invention and clinical development. By focusing on this capital gap, the Fund can advance technologies of high commercial potential and medical benefit to a stage where larger, more traditional investment sources are attracted to underwrite the risk.Types of Fund InvestmentsThe Partners Innovation Fund will make two types of investments: Equity and Development.Equity investments are seed and early financings that will catalyze company formation. These investments will often be a Series A stock and co-investors are frequently other early institutional investors, private investors or corporate investment funds.Development investments precede company formation and are intended to validate technologies with a high potential for later commercialization by either new venture formation or out-licensing to an existing market player.For all investments, funds will be reserved for participation in follow-on investments.Innovation Fund ProcessUtilizing a proven venture capital based diligence model, the team conducts in-depth diligence on all opportunities in two steps:1. Initial Screening: Assesses opportunities for high commercial potential. Key project attributes are:* Product concept and value proposition* Intellectual Property Position* Stage of technology development* Market Opportunity* Technology Review* Management Team* Regulatory pathway* Funding requirements* Competitive Analysis* Business Model 2. Evaluation and Investment Decision: During this step, PIF staff conducts extensive diligence to assess the strength of the proposed business in relation to our investment criteria. This process takes place over 3 to 6 months during which time we interact with technical and market experts, possible customers, competitors and potential co-investors as we prepare for presentation of the investment opportunity to our external Investment Committee for final approval.The team will work with investigators and their advisors to develop a project or business plan including connections to potential entrepreneurs, advisors and investors in the venture, private or corporate arena.Venture Launch / Ongoing Support: Once an investment has been approved, the Innovation Fund plays an active role in the ongoing development of the new venture. The team will work on all aspects required to move the new entity forward including recruiting senior management and staff, providing guidance and support in technology development, serving on the Board of Directors and working with management to achieve milestones.

## Contacts

5 contacts available for Partners Innovation Fund. Shizune tracks 8 team members at Partners Innovation Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/partners-innovation-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 24 | 51% |
| Health Care | 18 | 38% |
| Therapeutics | 11 | 23% |
| Medical | 10 | 21% |
| Pharmaceutical | 6 | 13% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 24 | 51% |
| Series B | 8 | 17% |
| Seed | 3 | 6% |
| Series C | 2 | 4% |
| Series D | 2 | 4% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 27 | 57% |
| France | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anne C. Pareti | Associate II | 0 | https://shizune.co/investors/profile/anne-c-pareti |
| Ellen Jung | Associate II | 0 | https://shizune.co/investors/profile/ellen-jung |
| Jessica M. Jacobs | Associate, Research & Licensing | 0 | https://shizune.co/investors/profile/jessica-m-jacobs |
| Michael Band | Manager, Business Development | 0 | https://shizune.co/investors/profile/michael-band |
| Pamela Keddy | Executive Assistant | 0 | https://shizune.co/investors/profile/pamela-keddy |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pykus Therapeutics | Pykus Therapeutics, Inc. was founded in 2016 to develop a dissolvable intraocular surgical device to make retinal surgery less painful and more successful.The co-founders were ophthalmology residents at the Massachusetts Eye and Ear Infirmary and Harvard Medical School when they developed a novel hydrogel to replace the use of intraocular gasduring retinal surgery. This innovation will eliminate the extreme burden placed on patients including the requirement for face-down positioning, inability to see for weeks, and inability to fly for weeks. | $2.5M | Venture - Series Unknown | Feb 04, 2021 |  |
| Verve Therapeutics | Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids suchas low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. | $63M | Series A | Jun 11, 2020 |  |
| ROME Therapeutics | ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. | $50M | Series A | Apr 27, 2020 |  |
| ROME Therapeutics | ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. | $50M | Series A | Apr 27, 2020 |  |
| SwanBio Therapeutics | SwanBio Therapeutics is a developer of a therapeutic technology designed to deliver dramatic clinical efficacy for the treatment of neurological diseases. The company's technology focuses on the development and commercialisation of genetically defined therapies for the treatment of neurological disorders. | $52M | Series A | Apr 23, 2020 |  |
| Affinia Therapeutics | Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle andcentral nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties. | $60M | Series A | Mar 31, 2020 |  |
| Keros Therapeutics | Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins,which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. | $56M | Series C | Mar 04, 2020 |  |
| Akouos | Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process,enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner. | $105M | Series B | Mar 03, 2020 |  |
| Triplet Therapeutics | Triplet is developing transformative therapies that treat repeat expansion disorders at their source. | $49M | Series A | Dec 17, 2019 |  |
| ZielBio | ZielBio is an early-stage biotechnology company that identifies novel high-value disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind combines the power of functional, high throughput screening with large content data analytics to identify high-value targets. They havea promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind.ZielBio was founded in 2011 and is based in Charlottesville, Virginia, United States. | $25.1M | Series A | Sep 26, 2019 |  |

10 of 47 investments shown.

## Co-investors
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 11 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 6 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 5 deals together
- [Apple Tree Partners](https://shizune.co/investors/profile/apple-tree-partners) — VC Fund, 4 deals together
- [Baxalta Ventures](https://shizune.co/investors/profile/baxalta-ventures) — VC Fund, 4 deals together
- [Mass Medical Angels](https://shizune.co/investors/profile/mass-medical-angels) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)

## FAQ

### What does Partners Innovation Fund invest in?

Partners Innovation Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 47 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Partners Innovation Fund?

Public channels for Partners Innovation Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Partners Innovation Fund?

The team at Partners Innovation Fund includes Anne C. Pareti (Associate II), Ellen Jung (Associate II) and Jessica M. Jacobs (Associate, Research & Licensing), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co